Obesity is a risk factor for many diseases including diabetes, cancer, cardiovascular disease, and chronic kidney disease. Obesity is characterized by the expansion of white adipose tissue (WAT). Hypertrophy and hyperplasia of adipocytes cause tissue hypoxia followed by inflammation and fibrosis. Its trigger, preadipocyte differentiation into mature adipocytes, is finely regulated by transcription factors, signal molecules, and cofactors. We found that echinomycin, a potent HIF-1 inhibitor, completely inhibited adipogenesis in 3T3-L1 WAT preadipocytes by affecting the early phase of mitotic clonal expansion. The dose required to exert the effect was surprisingly low and the time was short. Interestingly, its inhibitory effect was independent of HIF-1 pathways. Time-course DNA microarray analysis of drugtreated and untreated preadipocytes extracted a major transcription factor, CCAAT/enhancer-protein β, as a key target of echinomycin. Echinomycin also inhibited adipogenesis and body weight gain in high fat diet mice. These findings highlight a novel role of echinomycin in suppressing adipocyte differentiation and offer a new therapeutic strategy against obesity and diabetes.
. Echinomycin inhibits adipogenesis in 3T3-L1 cells in a time-and dose-dependent manner. (A) Protocol for preadipocyte differentiation and echinomycin treatment: two days after 3T3-L1 cells reached full confluence, they were treated with medium containing a differentiation cocktail containing MDI [10% FCS, 3-isobutyl-1-methylxanthine (0.5 mM), dexamethasone (1 μM), and insulin (10 μg/ml)] for 2 days, and then, for an additional 3 days, the cells were maintained in DMEM containing 10% FCS and insulin (10 μg/ml). Echinomycin or DMSO was added to medium with MDI, and after the times (hr) indicated in each experiment, cells were gently washed to remove echinomycin or DMSO, and the medium was exchanged with fresh medium containing MDI. . Quantification of the Oil red O staining was performed by eluting the dye with isopropanol and measure the OD 490 nm absorbance. The quantification data are the mean ± SEM of echinomycin on adipocyte differentiation, 3T3-L1 preadipocytes were treated with various concentrations and/or durations of echinomycin simultaneously with MDI ( Fig. 1B ). Echinomycin inhibited adipogenesis in a time-and dose-dependent manner. Even under re-stimulation with MDI 6 hr after MDI plus echinomycin treatment, cells failed to differentiate into mature adipocytes ( Fig. 1B left upper panel) . Treatment with 6 nM for 6 hr was sufficient to fully inhibit adipogenesis, and we used this condition in the following studies unless otherwise indicated. This treatment concentration and time is within the range of previously reported usage of echinomycin in cancer cells (e.g., U-251 and HeLa cells) 7, 8, 10 . Accordingly, the altered expression levels of mature adipogenic marker genes such as fatty acid binding protein 4 (Fabp4), peroxisome proliferator-activated receptor γ (Pparg), and CCAAT/ enhancer-binding protein α (Cebpa) were blunted by echinomycin treatment (Fig. 1C ). On the other hand, the addition of echinomycin from 24 hr after induction was insufficient to abolish adipocyte differentiation (data not shown), which suggested that echinomycin exerts its effect on the early stage of adipogenesis.
Echinomycin Inhibits Adipogenesis Independently of HIF Activity. Echinomycin intercalates DNA
and binds to sequences including HRE sequences, that is, GCGTG or ACGTG, inhibiting HIF transcriptional activity. In 3T3-L1 cells, 6 nM echinomycin treatment significantly reduced the increased HREluc reporter activity from MDI treatment ( Fig. 2A ), as well as the expression levels of representative HIF-1 target genes such as hexokinase 2 (Hk2), vascular endothelial growth factor A (Vegfa) (Fig. 2B ), and glucose transporter 1 (GLUT1) ( Fig. 2C ). Although HIF-1α was induced at 2 hr after MDI treatment, which was probably a PI3K/AKT-mediated response to insulin, this induction was very modest compared with that by hypoxic stimuli (Fig. 2D ). Although echinomycin is a DNA intercalater, it also affects the expression level of HIF-1α protein depending on the cell line 11 ; in 3T3-L1 cells, echinomycin reduced HIF-1α protein expression ( Fig. 2D left panel) . HIF-2α was not induced at this early time point ( Fig. 2D right panel) , which is in accordance with previous reports that HIF-2α is induced in much later phase of adipogenesis 12, 13 . These results demonstrate that the conventional effect of echinomycin as a HIF-1 inhibitor both in function and quantity also applies to 3T3-L1 cells.
On the other hand, hypoxia (1% O 2 ) inhibited adipocyte differentiation, which was demonstrated by Oil red O staining and its quantification ( Fig. 2E ). qRT-PCR for the mature adipocyte marker genes (e.g., Pparg, Fabp4, and Cebpa) at day 8 after MDI exposure also remained low under hypoxic condition ( Fig. 2F ). Previous studies have also reported that 3T3-L1 cells with knockdown of HIF-1α undergo adipogenic differentiation even under hypoxia, which implies that HIF-1 functions as an inhibitory signal in the cascade 12, 14 . Thus, if an effect of echinomycin on adipogenesis is mediated by the HIF pathway, echinomycin should have stimulated adipogenesis. Our results suggest that echinomycin inhibits adipogenesis independently of HIF pathways.
Transcriptome Analysis of Early Adipogenesis with or without Echinomycin. To investigate the molecular mechanism that underlies the effect of echinomycin on adipogenesis, gene expression profiling of 3T3-L1 cells during adipogenesis was performed with DNA microarrays at times 0, 2, 6, and 24 hr following treatment either with MDI plus DMSO or MDI plus echinomycin (6 nM for 6 hr). First, the 2,204 gene set probes that increased more than 2-fold compared with 0 hr among the time-course DMSO-treated control groups were selected and clustered into three groups ( Fig. 3A and Table S1 ). Different subsets of genes responded at different time points to MDI stimulation, consistent with previous reports 15 ; cluster 1 with genes responded as early as 2 hr after MDI treatment [e.g., CCAAT/enhancer-binding protein (Cebp) b, Cebpd, Kruppel like factor (Klf) 4, Klf5, and Klf9]; cluster 2 with genes such as fos-like antigen 1 (Fosl1) and integrin subunit alpha 5 (Itga5); and cluster 3 with genes such as a disintegrin, metallopeptidase domain 8 (Adam8) and hepatocyte growth factor (Hgf).
To focus on the gene expression profiles and their changes at the very early phase of adipogenesis, we compared gene expression profiles of cells treated with MDI plus DMSO and MDI plus echinomycin at 2 hr and 6 hr after induction. The 14,005 probes were distributed in all of the four quadrants at either 2 hr or 6 hr, which signified that some of the genes are even upregulated under echinomycin treatment, ruling out the possibility that echinomycin globally suppresses gene transcription (Fig. 3B ). The microarray analysis was validated by qRT-PCR for representative genes in adipogenesis (e.g., Cebpb, Cebpd, Klf4, and Klf5) (Fig. 3C ). The probes induced in both the 2 hr-and 6 hr-MDI plus DMSO treated groups more than 2-fold compared with 0 hr were extracted ( Fig. 3B-c) . The resulting 564 probes with annotation (out of 592 probes) were further clustered by centred average linkage ( Fig. 3D and Table S2 ). Because a 2 hr treatment with echinomycin was insufficient to inhibit adipogenesis ( Fig. 1B ), expression of the target genes of echinomycin was expected to be suppressed at both 2 hr and 6 hr. The cluster that met this criterion included 111 probes ( Fig. 3D and Table S2 ).
C/EBPβ as a Key Target of Echinomycin.
During early differentiation (24-48 hr following MDI treatment), 3T3-L1 cells are known to re-enter the cell cycle and undergo two to three cycles of clonal expansion before terminal differentiation 1, 16, 17 . The fact that re-stimulation with MDI 6 hr after echinomycin treatment failed to induce adipocyte differentiation supports the hypothesis that echinomycin inhibited this critical phase of clonal expansion. We observed that cell proliferation was inhibited in an echinomycin-dose-dependent manner in this period, supporting our hypothesis ( Fig. 4A and B ). Gene ontology analysis of the above 111 probes by DAVID also showed significant enrichment (enrichment score 4.65, P < 4.5 × 10 −7 ) in transcriptional regulation three independent experiments. *P < 0.05, **P < 0.01, as determined by a two-way ANOVA with Bonferroni's post-test. (F) qRT-PCR analysis of mature adipocyte gene expression in 3T3-L1 cells at day 8 under hypoxia. Mature adipogenic genes such as Pparg, Cebpa, and Fabp4 induced by MDI were suppressed by hypoxic condition (1% O 2 ). The data are expressed as the mean ± SEM from three independent experiments. **P < 0.01, as determined by one-way ANOVA with Tukey's post-test. Three members of the C/EBP family, C/EBPβ, C/EBPδ and C/EBPα, play crucial roles in adipocyte differentiation 18, 19 . In the very early phase of adipogenesis, C/EBPβ and C/EBPδ are induced, and these in turn activate PPARγ and C/EBPα, which play central roles in the rest of the regulatory cascade in adipocyte differentiation [20] [21] [22] . Mice lacking C/EBPβ display reduced depots of WAT, a phenotype exacerbated in C/EBPβ−/−/C/EBPδ−/− mice 23 . Whereas Cebpb was extracted as one of the top candidate target genes of echinomycin, the expression level of Cebpd did not change following echinomycin treatment ( Fig. 3C and Table S2 ). Other adipogenic cascade regulators such as KLF5 and KLF9, which are listed as candidate genes in Fig. 4D , are known to be downstream of C/EBPβ and thus are not expected to be a direct target of echinomycin. In addition, genes upstream of Cebpb in the cascade, such as Creb, Klf4, and Krox20, were not affected by echinomycin treatment either (Figs 3C and 4C, and Table S2) 24 . Supplementary Figure. Supplementary Figure. (D) (a) Mouse C/EBPβ stable overexpression 3T3-L1 clones were generated using a retroviral system and its C/EBPβ expression was confirmed by immunoblot analysis. Full-length blots are presented in Supplementary Figure. Enhanced C/EBPβ protein expression was suppressed by echinomycin continuously from 6 hr after adipogenic induction (Fig. 5A ). The result that 2 hr treatment with echinomycin was insufficient to inhibit adipogenesis (Fig. 1B) , and the fact that the expression of C/EBPβ in this period is a prerequisite for mitotic clonal expansion in adipogenic differentiation, both support the hypothesis that C/EBPβ is the target. MDI treatment increased the activity of the mouse Cebpb promoter, which was significantly decreased by echinomycin treatment, which indicated that echinomycin binds to Cebpb promoter and suppresses its transcription (Fig. 5B ). To rule out the possibility that C/EBPβ induction by MDI stimuli is dependent on HIF-1, loss-of-function mutations of HIF-1 transcriptional activity was introduced to 3T3-L1 cells through CRISPR/Cas9 system 25 . CRISPR/Cas9-mediated stable knockout 3T3-L1 cells of the Hif1a gene was generated by puromycin screening and selecting positive clones using the HREluc assay ( Fig. 5C left panel) . Knockout of Hif1a did not suppress the induction of C/EBPβ under MDI stimuli, which indicates that C/EBPβ induction is independent of HIF-1, and that the effect of echinomycin on C/EBPβ is not mediated by HIF-1. In addition, 3T3-L1 cells with retrovirus transduction of C/EBPβ (Fig. 5D-a) escaped from the suppression of adipogenesis by echinomycin ( Fig. 5D-b) . These results strongly point to C/EBPβ as the main target of echinomycin.
Echinomycin Inhibits Adipogenesis in vivo.
To further investigate the effect of echinomycin on adipogenesis in vivo, male C57BL/6Jcl mice were fed with high-fat diet (HFD) for 2.5 weeks. Echinomycin was intraperitoneally injected at two doses and frequency for the entire period based on the previous reports in mice and humans 26, 27 : 10 μg/kg for 5-days on/2-days off (EC-Low), or 50 μg/kg every alternate day (EC-High). These regimens are much milder than those used in human clinical trials for anti-cancer treatment. Each regimen effectively inhibited the HIF-1 activity (shown by the qRT-PCR for Vegfa) in the epididymal white adipose tissue (eWAT) of both normal fat diet (NFD) and HFD mice, which demonstrated that echinomycin was effectively delivered to eWAT (Fig. 6A ). Each echinomycin treatment inhibited the body weight gain (Fig. 6B) , without effects on the food intake (data not shown). eWAT/gBW and qRT-PCR of the established HFD-induced gene 28 , leptin, were analysed among each group, which confirmed that echinomycin inhibited adipogenesis in vivo ( Fig. 6C and D) . H&E staining of eWAT accordingly demonstrated that echinomycin efficiently suppressed the adipocyte size in HFD mice (Fig. 6E ). These results are in accordance with the in vitro results.
Discussion
Our current study demonstrates that echinomycin, a DNA intercalater, completely inhibits adipogenesis in the 3T3-L1 adipocyte cell line of WAT, as well as in eWAT of HFD mice. A DNA transcriptome array extracted one of the essential adipogenic transcription regulators, C/EBPβ, as its major target (Fig. 7 ).
An advantage of this small molecule is that a relatively small dose and short-term treatment are sufficient to exhibit its effect. Echinomycin is traditionally known as a HIF-1 inhibitor 7, 8 . It binds to HRE sequences and decreases HIF-1 transcriptional activity. Whether echinomycin affects the expression of HIF-1α protein depends on the cell line; in U251, HepG2, and HeLa cells, HIF1-α protein level is not affected 7, 8, 10 ; in MCF-7 cells, it is decreased 11 . In 3T3-L1 cells, echinomycin inhibited HIF-1α protein expression and HIF-1 activity.
The in vivo functional role of HIF-1 in adipogenesis of WAT is controversial. Some reported that adipocyte-specific genetic deletion of HIF-1α protects obese mice from insulin resistance and inflammation, whereas constitutively active expression of HIF-1α results in increased insulin resistance and tissue fibrosis 3 . In these knockout mice, white adipose tissue mass and mean adipocyte size are increased 4, 12 , which implies that HIF-1 in the end inhibits adipogenesis in WAT. Others, on the other hand, reported the opposite results using the same aP2 promoter-driven adipocyte-specific Hif1a deleted mice 29, 30 . HIF-1 deficiency improved HFD-induced insulin resistance and reduced WAT adipocity. In vitro studies using 3T3-L1 cells show that hypoxia inhibits adipogenesis through HIF-1 12, 14 . Our results also demonstrate that while HIF-1α is induced as early as 2 hr and again from 12 hr after adipogenic induction (data not shown), adipogenesis is suppressed under hypoxia. These findings suggest that although the temporal induction of HIF-1 in the early course of adipogenesis may have some functional roles in regulating the growth arrest and differentiation of preadipocytes, it acts as an inhibitory signal for adipogenesis. Of note, while HIF-2α is known to promote adipogenesis in 3T3-L1 cells, previous reports suggest that HIF-2α is induced at later phase of adipogenesis, from 4 day after MDI induction 12, 13 . We confirmed that HIF-2α was not induced at least until 24 hr after MDI induction (data not shown), and that the inhibitory effect of echinomycin on adipogenesis was unlikely to be mediated by HIF-2.
In contrast to our original expectation, our results demonstrated that echinomycin exerted its inhibitory effect on adipogenesis independently of the HIF pathway. Adipocyte differentiation is precisely controlled by a complex network of transcription factors, cofactors and signalling molecules. A comprehensive DNA microarray analysis was performed, and C/EBPβ was identified as a key target of echinomycin in the adipogenic cascade. C/EBPβ is known as an indispensable adipogenic transcription factor, and ectopic overexpression of C/EBPβ is sufficient to induce PPARγ and subsequent adipocyte differentiation. Continuous suppression of C/EBPβ was observed both at mRNA and the protein level, while C/EBPδ remained unaffected. An in silico search predicted several HRE sequences in the promoter region of Cebpb, which are potential binding sites for echinomycin, and the loss of this echinomycin effect in Cebpb promoters smaller than 1 kbp suggests that echinomycin inhibits the Cebpb transcription and its binding site exists between 2 k and 1 k in the promoter region. None of their mutations, however, cancelled the effect of echinomycin on the promoter activity (data not shown), which prevented us from drawing an unequivocal conclusion on its binding site. These observations have two implications for the mechanism of action of echinomycin on C/EBPβ; Echinomycin binds to a Cebpb promoter region which is yet to be identified, or, echinomycin binds to an upstream gene of Cebpb, which results in the transcriptional inhibition of C/EBPβ. Although our microarray results and Cebpb promoter assay favour the former story, the exact mechanism of action of echinomycin on C/EBPβ remains to be a subject of future research. There are some other reports on inhibitory molecules against adipogenesis. Rapamycin, an inhibitor of mammalian target of rapamycin, suppresses adipogenic differentiation through its anti-proliferative activity 31 . Pyridinyl imidazoles also block 3T3-L1 adipogenesis by targeting p38 mitogen-activated protein kinase 32 . Our study gives an additional insight into how adipogenesis could be blocked by a temporal intervention. It is also unique that it affects the very early phase of transcriptional cascade.
Taken together, our results demonstrate a novel effect of echinomycin beyond its anti-tumour activity, by acting on adipocyte differentiation. Echinomycin inhibits adipogenesis of 3T3-L1 cells in a HIF-independent manner. Time-course DNA microarray analysis of drug-treated and untreated preadipocytes extracted a major transcription factor, CCAAT/enhancer-protein β, as a key target of echinomycin. The effect of echinomycin also 
Materials and Methods
Reagents. Insulin, dexamethasone (DEX), 3-isobutyl-1-methylxanthine (IBMX), and oil red O were purchased from Sigma (Sigma-Aldrich, St Louis, MO). Echinomycin (Calbiochem, Gibbstown, NJ) was dissolved in DMSO (Wako, Tokyo, Japan) according to the manufacturer's instructions.
Cell Culture, Differentiation, and Drug Treatment. 3T3-L1 cells (American Type Culture Collection, Rockville, MD) were cultured in Dulbecco's modified Eagle's medium (DMEM, Nissui, Tokyo, Japan) supplemented with 10% calf serum (CS). The differentiation protocol is as described previously 33 . Briefly, two days after cells reached confluence (Day 0), the medium was replaced with a mixture consisting of 10% FCS and MDI (0. 5 mM IBMX, 1 μM DEX, and 10 μg/ml insulin). After 48 h, the medium was changed to DMEM containing 10% FCS and 10 μg/ml insulin. The medium was replenished at 2-day intervals, and the appearance of cytoplasmic triglycerides was monitored by microscopy and confirmed by staining with oil red O. For hypoxic stimulation, cells were exposed to 1% O 2 /5% CO 2 , with nitrogen as the balance, in a multigas incubator, APM-30D (ASTEC, Fukuoka, Japan). Luciferase Reporter Assay. HIF-1 transcriptional activity (HREluc activity) was measured by dual-luciferase reporter assays (Promega, Madison, WI) in 24-well culture dishes. Five-hundred nanograms of pGL3 (Promega) vector driven by 7× hypoxia-responsive elements (pHREluc) 34 and 25 ng of Renilla luciferase vector (pRL-TK or pRL-CMV) were co-transfected using Lipofectamine LTX (Invitrogen, Carlsbad, CA); 2 days after full confluence, the cells were differentiated as above and exposed to hypoxia (1% O 2 ) for 8 hr. The cells were processed in fixed protein aliquots, and HREluc activity was measured using a Lumat 9507 luminometer (EG and Berthold, Bad Wildbad, Germany). The relative light unit (RLU) value of firefly luciferase was divided by that of Renilla luciferase to correct for the transfection efficiency. To measure Cebpb promoter activity, a similar method to the above was used. Cebpb promoter fragments of 3 kb, 2 kb, 1 kb, or 0.5 kb (mCEBPB3K, 2 K, 1 K, or 0.5 K promoter) were PCR amplified from mouse genomic DNA using PrimeStar HS DNA polymerase (Takara Bio, Shiga, Japan) and primers with KpnI and XhoI overhangs (see Table 1 for primers). Digested and purified fragments were inserted into the pGL3basic reporter vector (Promega).
Plasmids and Stable
Overexpression. 3T3-L1 clones, which stably overexpress C/EBPβ, were generated with retrovirus transduction (Platinum Retrovirus Expression System, Pantropic, Cell Biolabs, San Diego, CA). pcDNA-mC/EBPb was a gift from Jed Friedman (Addgene plasmid #49198). The plasmid was digested with XhoI and PmeI, and subcloned into the retroviral vector, pMXs-IRES-Puro using the XhoI-SnaBI site. The plasmids were transfected to the packaging cell line, and the culture supernatants were collected 24 and 48 hr later, passed through 0.22-μm filters, and added to the cells. Drug selection by 2 μg/ml puromycin was initiated 72 hr after infection. For CRISPR-Cas9 system, pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid #42230) 24 . Hif1a target sgRNAs were designed by using CRISPRdirect 35 , and ligated into pX330 plasmid by following the procedures from Zhang lab (http://www.genome-engineering.org/crispr). Sequences are listed in Table 1 . 3T3-L1 cells were co-transfected with the two pX330-Hif1a and a puromycin resistant plasmid which facilitates selection with puromycin (2 μg/ml). Selected colonies went further selection by HREluc activity under hypoxia.
Microarray Analysis.
A transcriptome microarray analysis of 3T3-L1 cells was conducted at 0 hr, 2 hr, 6 hr, and 24 hr of treatment with either MDI plus DMSO or MDI plus echinomycin (6 nM). For the 24-hr samples, cells were washed and re-incubated with MDI 6 hr after induction. Total cellular RNA was isolated using RNAiso plus (Takara Bio). cRNA was synthesized from cellular RNA and hybridized to high density Affymetrix microarray gene chips containing 45,102 probe sets. The expression value for each mRNA was obtained using the Robust Multi-array Analysis (RMA) method. Probes with normalized intensity lower than 100 in all seven arrays (31,097 probes) were excluded from the analyses, which left 14,005 probes for further analysis. To identify the transcripts that were increased by MDI treatment, all probes with a fold change >= 2.0 in expression (either 2, 6, or 24 hr after MDI + DMSO treatment) compared with the control (time 0 hr) were selected (2,204 probes), and hierarchical clustering analysis was performed using the average linkage and relative correlation as a measure of similarity for the selected genes. To identify transcripts that are significantly induced by MDI and suppressed both at 2 hr and 6 hr after echinomycin treatment, the following selection procedures were performed. All probes that had a fold change >= 2.0 in expression compared with the control (time 0 hr) at both two time points, 2 hr and 6 hr, were first selected (592 probes). After excluding probe sets that did not have gene annotation, the remaining 564 probes were used for further analyses. Hierarchical clustering analysis of a log 2-fold change from the control (time 0 hr) was performed using the average linkage and relative correlation as a measure of similarity for the selected genes. The Database for Annotation, Visualization and Integrated Discovery (DAVID) 36, 37 , an online gene database provided by the NIH (version 6.8; http://david.abcc.ncifcrf.gov/), was used to investigate biological functions associated with the gene lists.
RNA Isolation and Real-Time Quantitative RT-PCR (qRT-PCR)
. RNA isolation and real-time quantitative (q) RT-PCR assays were performed as previously described 38 . The data were calibrated to the β-actin value. The primers are described in Table 1 . Table 1 . A list of primers used in this study.
